Company Updates

Introducing The More Life Company

This morning, we announced the completion of our corporate name change from Mountain Valley MD to The More Life Company.

MVMD Shareholder Update: Strengthening the Team for Our Next Phase

This morning we announced the appointment of five additional advisors to MVMD,

MVMD Shareholder Update – Quicksome™ Technology and the Emerging Peptide Opportunity

Quicksome™ Technology and the Emerging Peptide Opportunity

Spring 2026 Shareholder Update

Happy New Year from MVMD!

MVMD enters 2026 positioned to convert validated progress across nutraceuticals, agriculture, and husbandry into disciplined, science-backed commercial growth through focused execution and responsible capital allocation.

December Shareholder Update - Agrarius Commercial Progress

Agrarius Commercial Progress

MVMD Summer 2025 Shareholder Update

This morning, we released a formal business update media release summarizing some of MVMD’s key advancements over the first half of the year.

Agrarius™ Update: Advancing Toward Commercial Scale

Agrarius™ is entering a pivotal commercialization phase, backed by successful global trials and strong market demand for sustainable agricultural solutions.

MVMD Year-End Shareholder Update

MVMD CEO, Dennis Hancock, shares a Year-End Business Update

MVMD Progress Update

Over the past six months, MVMD has experienced transformative progress across our three main business lines, demonstrating the differentiation and positive reception of our technologies in the marketplace.

MVMD Secures Agrarius Territory Exclusivity and Introduces Performance Guarantee Program

MVMD has acquired the exclusive license and distribution rights for the Agrarius™ technology across Canada and the USA, Mexico, South America, Central America, and the Caribbean. We will also retain our global non-exclusive rights outside of this exclusive territory.

MVMD Business Update

MVMD President and CEO, Dennis Hancock, provides commercialization progress update.

Eons Launches Deeper Sleep Powered by Quicksome™

Eons Launches Deeper Sleep Rapid Dissolve Mushroom Tablets powered by MVMD's proprietary Quicksome™ technology.

MVMD Business Update

It's been one year since I shared with our shareholders that MVMD was commencing our transition from an R&D-focused biotech start-up business into a commercially focused biotech entity.

2023 AGM Business Presentation Video

Watch MVMD's 2023 AGM hosted on September 28th, 2023

MVMD Business Update

MVMD Business Update by Dennis Hancock, President & CEO of MVMD.

MVMD executes license agreement, related studies, and patent expansion for Soluvec™

MVMD executes license agreement, related studies, and patent expansion for Soluvec™

MVMD Business Progress Update Video

MVMD Business Progress Update Video

MVMD Welcomes Dr. Elizabeth Norton to Advisory Role / Cold Chain and Vaccine Progress

MVMD Welcomes Dr. Elizabeth Norton to Advisory Role / Cold Chain and Vaccine Progress

Register for MVMD's 2022 AGM – Wednesday, September 29th

Register for MVMD AGM – Wednesday, September 29th

MVMD Welcomes Two New Advisors to the Team

The addition of Gokul Kannan and Mark Gelnaw to the MVMD team is expected to bring significant value as we continue to advance our key oncology and technology initiatives.

MVMD Update: FDA, Oncology, Cold Chain, Husbandry and more

MVMD Update: FDA, Oncology, Cold Chain, Husbandry and more

MVMD Selactosol™ Interview

Mike Farber and Steve Darling from Proactive Investor discussed MVMD's new water-solubilized selamectin breakthrough

New MVMD Dose Sparing Patent Filed

MVMD Files for a new, novel dose sparing patent for IPV Polio